In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model
2019
Background
Plasma concentration of low-density lipoprotein (LDL) cholesterol is a well-established risk factor for cardiovascular disease. Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9), which regulates cholesterol homeostasis, has recently emerged as an approach to reduce cholesterol levels. The development of humanized animal models is an important step to validate and study human drug targets, and use of genome and base editing has been proposed as a mean to target disease alleles.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
54
References
33
Citations
NaN
KQI